<DOC>
	<DOCNO>NCT00046514</DOCNO>
	<brief_summary>The anticancer agent paclitaxel ( market Taxol ) show remarkable activity metastatic breast cancer . However , Taxol formulation require prolonged administration time , safety problem attribute solvent rather active ingredient , paclitaxel . This new formulation paclitaxel find few safety problem Taxol , may administer safely high dos . This study investigate safety efficacy new formulation paclitaxel give intravenously week three week , follow rest week . This cycle repeat safety problem treatment failure require patient stop therapy .</brief_summary>
	<brief_title>ABI-007 Taxol Resistant Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>The anticancer agent paclitaxel ( Taxol Injection Concentrate , Bristol-Meyers Squibb ) broad spectrum activity several human cancer include carcinoma ovary , breast , lung , esophagus head neck cancer . Taxol show remarkable activity metastatic breast cancer , yield response rate range 40 % 60 % chemotherapy-naive patient 25 % -30 % patient refractory anthracycline-containing regimen ( Taxol package insert ) . The major limitation Taxol poor water soluability require Cremophor ( contain castor oil ethanol ) solvent . Taxol vehicle must administer 3-24 hour , hypersensitivity reaction Cremophor require premedication routine corticosteroid , antihistamine , H2 antagonist . In study , test medication ( ABI-007 ) nanoparticle colloidal composition protein-stabilized paclitaxel reconstitute saline . The infusion time ABI-007 minimal compare Taxol ( hour ) , premedication require . The maximally tolerate dose formulation paclitaxel 300 mg/m2 , compare 175 mg/m2 Taxol . As tumor response show dose-dependent paclitaxel , high dose allow potentially good response . This open-label , Phase II study determine safety , tolerability anti-tumor effect ABI-007 monotherapy administer weekly patient metastatic breast cancer previously treat Taxol .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Patients must : If female , nonpregnant lactating , negative serum pregnancy test , either childbearing potential practicing approve contraception method Eighteen year age old Karnofsky Perfomance Status 70 % 02 SWOG Performance Status No malignancy , except nonmelanoma skin cancer , CIN , insitu cervical cancer Measurable disease Suitable candidate treatment paclitaxel Previously treat Taxol weekly every three week , include adjuvant therapy , metastatic breast cancer relapse within 12 month If , baseline , patient absolute neutrophil count least 1500 cells/mm3 , platelet count least 100,000 cells/mm3 , hemoglobin least 9 g/dL If , baseline , patient AST ALT less equal 2.5 x upper limit normal range ; total bilirubin less equal 1.5 mg/dL ; creatinine level less equal 2 mg/dL ; alkaline phosphatase level less equal 5 x upper limit normal range ( unless bone liver metastasis ) Patient expect survival least 12 week Patient his/her representative sign informed consent statement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Taxol</keyword>
</DOC>